Argent Biopharma Ltd

As of June 30, 2025, Argent Biopharma Ltd carries a market capitalization of 1.88M, placing it among publicly traded companies globally. Its enterprise value stands at 5.93M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Argent Biopharma Ltd's next confirmed earnings release is scheduled for March 3, 2027.

As of June 30, 2025, Argent Biopharma Ltd has 72.18M shares outstanding.

These figures are as of June 30, 2025. The price-to-sales ratio is 4.56, and the price-to-book ratio stands at -0.39.

These figures are as of June 30, 2025. The EV/Sales ratio of 18.21 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 5.93M versus a market cap of 1.88M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2025, Argent Biopharma Ltd maintains a current ratio of 0.19, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -96.03, indicating conservative leverage, while an interest coverage ratio of -344.75 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2025. Return on assets (ROA) is negative at -269.25, reflecting losses generated across the asset base. Inventory turnover of 0.27 indicates how many times Argent Biopharma Ltd sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, Argent Biopharma Ltd's stock has declined approximately 73.40% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.02.

Over the twelve months ended June 30, 2025, Argent Biopharma Ltd generated 325,822.55 in revenue and converted that into -9.97M in net income, yielding earnings per share of -0.17. EBITDA reached -9.88M, while operating income came in at -8.62M.

As of June 30, 2025, Argent Biopharma Ltd holds 572,072.95 in cash and equivalents against 4.63M in total debt, resulting in a net debt position of 3.86M. Total book value stands at -4.82M, with working capital of -4.91M providing operational flexibility.

These figures cover the twelve months ended June 30, 2025.

Over the twelve months ended June 30, 2025, Argent Biopharma Ltd posted a gross margin of 76.50, reflecting its pricing power and cost economics. The operating margin of -2,646.84 and net profit margin of -3,058.43 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2025. Total shareholder yield is negative at -279.48, meaning Argent Biopharma Ltd raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Argent Biopharma Ltd's most recent stock split took place on October 30, 2023 with a 1000:1 split ratio.

As of June 30, 2025, Argent Biopharma Ltd has an Altman Z-Score of -108.20, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.